ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 129

Identifying Predictors Of A Fibromyalgia Diagnosis: A Retrospective Electronic Medical Record Analysis

Elizabeth T. Masters1, Jack Mardekian1, Andrew Clair1 and Stuart L. Silverman2, 1Pfizer Inc, New York, NY, 2Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: data analysis and fibromyalgia, Electronic Health Record

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders and Pain I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Fibromyalgia (FM) is a chronic pain condition characterized by a constellation of symptoms and comorbidities. Consequently, FM diagnosis can be challenging and it often goes undetected. This study used electronic medical record (EMR) data to identify factors associated with FM that may facilitate earlier identification and diagnosis.

Methods: Subjects ≥18 years old who had ≥1 diagnosis code for common pain conditions were extracted from the Humedica de-identified EMR database, which has broad geographic representation and includes information on demographics, diagnoses, inpatient/outpatient encounters, medications, procedures, lab results, and select data from physicians’ notes. Records are linked using a unique patient identifier. Subjects with continuous enrollment in an integrated healthcare delivery system in 2010 and a first FM diagnosis in 2011 (cases) were compared with subjects without an FM diagnosis during 2011 (controls). Patients with an FM diagnosis prior to 2011 were excluded. FM diagnosis was based on ICD-9 code 729.1 (myalgia and myositis, unspecified). Sequential stepwise logistic regression was performed with FM diagnosis as the response variable, and demographic, clinical, and healthcare resource use as predictor variables. Variables with significant associations (P≤.05) were retained in the model and expressed as odds ratios (OR) with their 95% confidence intervals (95% CI).

Results: Subjects were 2,823 individuals with an FM diagnosis and 210,495 without an FM diagnosis in 2011. Although mean (SD) age was similar between groups, 51.4 (15.3) years for cases and 51.4 (16.4) years for controls, the FM population had more females (72.3% vs 60.4%; P<.0001), and significant differences between groups were observed for other baseline characteristics including race and healthcare resource use (higher in cases; P<.001), and the presence of specific comorbidities (higher in cases; P≤.05). The model identified 17 variables significantly associated with an FM diagnosis. The first variable (i.e., the variable with the smallest p-value when included as a predictor by itself) that made it into the model was the number of pain medication prescriptions (OR 1.03 (95% CI 1.02, 1.04), followed by the number of musculoskeletal pain conditions (OR 1.19 (95% CI 1.16, 1.23). Several clinical variables, including the presence of gastrointestinal and sleep disorders were also predictive: OR 1.38 (95% CI 1.26, 1.51) and 1.33 (95% CI 1.15, 1.55), respectively. Other healthcare resource utilization variables that entered into the model included number of outpatient visits and hospitalizations. 

Conclusion: The model identified several demographic and clinical variables as significant predictors of an FM diagnosis. These results suggest analysis of EMR data can help identify variables associated with FM in a real world setting, and may inform earlier identification of FM patients.


Disclosure:

E. T. Masters,

Pfizer Inc,

1,

Pfizer Inc,

3;

J. Mardekian,

Pfizer Inc,

1,

Pfizer Inc,

3;

A. Clair,

Pfizer Inc,

1,

Pfizer Inc,

3;

S. L. Silverman,

Amgen, Lilly, Medtronics and Pfizer/Wyeth ,

2,

Amgen, Lilly, Pfizer/Wyeth,

8,

Amgen, Genetech, Lilly, Novartis, Pfizer/Wyeth ,

5,

Cedars-Sinai Medical Center ,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-predictors-of-a-fibromyalgia-diagnosis-a-retrospective-electronic-medical-record-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology